Search - tctmd.com

Displaying 261 - 280 of 602

Sort: Relevancy | Date

Presentation TCT 2017

Impact of AUC and Public Reporting: Is PCI Now More Appropriate?

Presenter: Dean J. Kereiakes, Spencer B. King III, Michael A. Kutcher

October 30, 2017

Presentation TCT 2017

Metallic DES: What Can We Expect From New Drugs, Polymers, and Metals? Have We Reached the Limit of Iterative Development?

Presenter: Dean J. Kereiakes, Spencer B. King III, Elazer R. Edelman

October 30, 2017

Presentation TCT 2017

New Insights Into Neoatherosclerosis and Other Causes of Metallic Stent Thrombosis: Will the Most Dreaded Complication Always Be With Us?

Presenter: Dean J. Kereiakes, Spencer B. King III, Aloke V. Finn

October 30, 2017

Presentation TCT 2017

Is There a Need for Dedicated Bifurcation Stents (Bare Metal or Drug-Eluting)?

Presenter: Alaide Chieffo, Jeffrey W. Moses, Martin B. Leon

October 30, 2017

Presentation TCT 2017

Very Late Stent Failures and Non-Stent Related Events: Insights Into Improving Event-Free Survival

Presenter: Dean J. Kereiakes, Spencer B. King III, Lorenz Raber

October 30, 2017

Presentation TCT 2017

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

Presenter: Dean J. Kereiakes, Spencer B. King III, Robert A. Byrne

October 30, 2017

Presentation TCT 2017

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

Presenter: Fernando Alfonso, Jose P.S. Henriques

October 30, 2017

Presentation TCT 2017

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Binita Shah

October 29, 2017

Presentation TCT 2017

Drug-Eluting Stent Platforms and Outcomes 2017

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Gennaro Sardella

October 29, 2017

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

Presentation TCT 2016

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Giulio Guagliumi

November 02, 2016

Presentation TCT 2016

Choose a Drug-Eluting Stent: Heres Why

Presenter: George D. Dangas, Fabio Felice Tarantino, Carlo Cernetti

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Presenter: Philip M. Urban, Stephen G. Worthley, Bonnie H. Weiner

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Dmitriy N. Feldman, Emmanouil S. Brilakis

November 01, 2016

Advertisement

Impact of AUC and Public Reporting: Is PCI Now More Appropriate?

Metallic DES: What Can We Expect From New Drugs, Polymers, and Metals? Have We Reached the Limit of Iterative Development?

New Insights Into Neoatherosclerosis and Other Causes of Metallic Stent Thrombosis: Will the Most Dreaded Complication Always Be With Us?

Is There a Need for Dedicated Bifurcation Stents (Bare Metal or Drug-Eluting)?

Very Late Stent Failures and Non-Stent Related Events: Insights Into Improving Event-Free Survival

Keynote Lecture: A Brief 40-Year History of PCI - How Far We've Come, How Far We Have to Go

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Drug-Eluting Stent Platforms and Outcomes 2017

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Choose a Drug-Eluting Stent: Heres Why

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content